OncoSil Medical (ASX: OSL) CEO & Managing Director Nigel Lange presented the company recently to investors, providing more detail into the nature of the treatment, clinical trials, and some indications as to how the recent capital raise is being used. In this article, we provide a summary of the main points from the Webinar, charting out the progress from Oncosil so far and important details about when the CEO expects it to break even.
OncoSil™ is intended for intratumoral implantation into a pancreatic tumour via injection under an endoscopic ultrasound guide. The treatment has already been used on over 200 people and counting.
Clinical Trials Are Continuing
Although Oncosil has been used to treat several patients, regulators would like further confirmation about its safety record. The CEO noted that the current trials in the Netherlands will ensure that they expand their user base. This will ensure that Oncosil is used across a range of jurisdictions safely, especially as it is already approved in 35 countries. The CEO noted that regulatory bodies take the time needed before issuing approval to a product as approvals come with a great deal of reputational risk. However, it appears that there will be some news regarding trials in the not-too-distant future.
Will OncoSil Break Even Soon?
According to CEO Nigel Lange, Oncosil will likely break even in 2025 or 2026. This is contingent on the pace of the clinical trials which can be notoriously long, but its presence in a growing number of countries means that Oncosil (ASX: OSL) will likely break even soon.
Oncosil is expanding in Australia and New Zealand Treatments to Resume
Oncosil has added two clinical trials in Australia, which include Epworth and Melbourne as well as the Royal Adelaide Hospital in the TRIPP-FXX study.
Clinical Trials and Treatments in Hong Kong
Oncosil is equally expected to become active in Hong Kong as hospitals have to meet some local requirements to administer the treatment. Getting access to the China Bay area means having regulatory approval from Hong Kong. The capital raise is, therefore, important in supporting expansion efforts.
The Investor presentation with Oncosil CEO, Nigel Lange, gave investors unique insights and perspectives on Oncosil’s activities. While much of the information is available in annual reports, there were unique insights that gave investors a better understanding of how Oncosil is progressing and how its recent capital rise will be used to advance its operations across the world.
